



RECEIVED

JUL 18 2003

#79/B  
7/29/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTER 1600/2900

Applicant(s)	Levi, et al.	Examiner:	Raymond J. Henley III
Serial No.:	10/076,204	Group Art Unit:	1614
Confirmation No:	8595	Docket:	955-16
Filed:	February 13, 2002	Dated:	July 16, 2003
For:	<b>Method and Compositions for Reducing Cardiac Dysfunctions with a Selective Histamine H<sub>3</sub> Receptor Agonist</b>		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

*I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450  
20231 on July 16, 2003*

*Dated: 7/16/03*

*Julie L. Watts*


PRELIMINARY AMENDMENT

Sir:

Applicants respectfully request entry of the following amendment prior to examination of the above-identified application.

**Amendments to the Claims** are reflected in the listing of claims which begin on page 2 of this Amendment.

**Remarks** begin on page 6 of this Amendment.



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s)	Levi, et al.	Examiner:	Raymond J. Henley III
Serial No.:	10/076,204	Group Art Unit:	1614
Confirmation No:	8595	Docket:	955-16
Filed:	February 13, 2002	Dated:	July 16, 2003
For:	<b>Method and Compositions for Reducing Cardiac Dysfunctions with a Selective Histamine H<sub>3</sub> Receptor Agonist</b>		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

*I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450  
20231 on July 16, 2003*

*Dated: 7/16/03*

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In the Office Action dated June 18, 2003, the Examiner has imposed a restriction requirement to one of the following inventions under the provisions of 35 U.S.C. §121:

- I. Claims 1-30, drawn to methods for reducing cardiac dysfunctions in a human (claims 1-18 and methods for inhibiting the Na<sup>+</sup>/H<sup>+</sup> exchanger in a human (claims 19-30) in each of which, *inter alia*, a pharmaceutical composition comprising a selective histamine H<sub>3</sub> receptor agonist is administered.
- II. Claims 31-32, drawn to a pharmaceutical composition comprising a selective histamine H<sub>3</sub> receptor agonist in a pharmaceutical carrier.


Application No.: 10/076,204  
Filing Date: February 13, 2002  
Docket No.: 955-16  
Page 2 of 2

Applicants hereby elect the claims of Group I, Claims 1-30, without traverse.

In addition, applicants co-filed herewith a Preliminary Amendment which amends claim 1 to more accurately define the invention and to cancel the non-elected claims.

In view of the present election and co-filed Preliminary Amendment, applicants respectfully submit that this application is now in condition for examination on the merits. If resolution of the any remaining issues are required prior to examination of the application, it is respectfully requested that the examiner contact the undersigned at the telephone number provided below.

Respectfully submitted,

  
Edna I. Gergel, Ph.D.  
Registration No.: 50,819  
Agent for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
EIG:jlw

175741\_1